BridgeBio is demonstrably improved this progress of an novel treatment for cardiac amyloidosis, leveraging the investigational drug. Initial trial data suggests potential improvements for those diagnosed from this https://biotech573581.idblogz.com/42467882/firm-advances-amyloidosis-management-using-attruby